nal-IRI

Phase 2Small molecule

Ipsen

nal-IRI is one of 188 small molecule programs targeting Gallbladder Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

187

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gallbladder CarcinomaActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

Esophageal AdenocarcinomaRecruiting

Metastatic Colorectal CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Gallbladder CarcinomaPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 2

Recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

nal-IRI

Ipsen

Phase 2

1 2

Gemzar

GGynecologic Oncology Group

MS Contin

1 4

Medrol

Pfizer

Preclinical

1 5

Byetta

AstraZeneca

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

LDE225

Novartis

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Thiazolidinediones

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Esophageal Adenocarcinoma

NCT04150640

Q4 2030

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07028424

Clinical

Trials by Indication[1]

Rectal Cancer1 trial

A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer

Completed·FFundación de investigación HM·Phase 2·NCT04009876·30 enrolled

Metastatic Colorectal Cancer1 trial

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Withdrawn·MMerrimack Pharmaceuticals·Phase 1/2·NCT02785068

Pancreatic Cancer1 trial

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Not yet recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT07028424·206 enrolled

Pancreatic Adenocarcinoma1 trial

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Completed· Ipsen logo

Ipsen·Phase 2·NCT02551991·56 enrolled

Gallbladder Carcinoma1 trial

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03043547·100 enrolled

1 more indication

Esophageal Adenocarcinoma1 trial

Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma

Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT04150640·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for nal-IRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nal-IRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nal-IRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Ipsen

nal-IRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2030

Trials by Indication[1]

Rectal Cancer1 trial

Metastatic Colorectal Cancer1 trial

Pancreatic Cancer1 trial

Pancreatic Adenocarcinoma1 trial

Gallbladder Carcinoma1 trial

Esophageal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News